Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food and CYP1A2 Induction on Pomalidomide PK
NCT02168205Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2014
- Primary completion
- Sep 2014
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pomalidomide in multiple myeloma (MM) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 4 more. Started May 2014; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02168205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168205.